1. Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: a systematic review and meta-analysis with meta-regression of observational studies
- Author
-
Katarzyna Nabrdalik, Mirela Hendel, Krzysztof Irlik, Hanna Kwiendacz, Igor Łoniewski, Tommaso Bucci, Uazman Alam, Gregory Y. H. Lip, Janusz Gumprecht, and Karolina Skonieczna-Żydecka
- Subjects
Gastrointestinal adverse events ,Diarrhea ,Dose ,Formulation ,Meta-analysis ,Metformin ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Abstract Introduction Metformin is the most prescribed medication for type 2 diabetes mellitus (T2DM); there is a well-established link with the elevated incidence of gastrointestinal (GI) adverse events (AE) limiting its administration or intensification. Objectives The objective of this systematic review and meta-analysis of observational studies was to evaluate the pooled incidence of GI AE related to metformin use in patients with T2DM. Materials and methods PUB MED/CINAHL/Web of Science/Scopus were searched from database inception until 29.07.2024 for observational studies in English describing the frequency of GI AE in patients with T2DM treated with metformin. Random-effects meta-analyses were used to derive effect sizes: event rates. Results From 7019 publications, we identified 211 potentially eligible full-text articles. Ultimately, 21 observational studies were included in the meta-analysis. The prevalence of GI AE was as follows: diarrhea 6.9% (95% CI: 0.038–0.123), bloating 6,2% (95% CI: 0.020–0.177), abdominal pain 5,3% (95% CI: 0.003–0.529), vomiting 2.4% (95%: CI 0.007–0.075), constipation 1.1% (95%: CI 0.001–0.100). The incidence of bloating (coefficient -4.46; p
- Published
- 2024
- Full Text
- View/download PDF